China Biologic Products Holdings Inc (NASDAQ:CBPO) Expected to Announce Earnings of $0.70 Per Share

Equities analysts expect China Biologic Products Holdings Inc (NASDAQ:CBPO) to announce earnings of $0.70 per share for the current quarter, Zacks reports. Zero analysts have provided estimates for China Biologic Products’ earnings. China Biologic Products posted earnings per share of $0.76 during the same quarter last year, which suggests a negative year over year growth rate of 7.9%. The company is expected to issue its next quarterly earnings report on Wednesday, March 4th.

On average, analysts expect that China Biologic Products will report full-year earnings of $4.17 per share for the current financial year, with EPS estimates ranging from $3.94 to $4.40. For the next year, analysts forecast that the business will report earnings of $4.38 per share, with EPS estimates ranging from $4.30 to $4.45. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for China Biologic Products.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Wednesday, November 13th. The biopharmaceutical company reported $1.40 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.52. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm had revenue of $136.10 million for the quarter. During the same period in the previous year, the firm posted $0.96 earnings per share. The business’s revenue for the quarter was up 14.3% on a year-over-year basis.

Several research firms recently commented on CBPO. Zacks Investment Research cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. ValuEngine upgraded shares of China Biologic Products from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, BidaskClub cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $92.67.

Several institutional investors and hedge funds have recently bought and sold shares of CBPO. York Capital Management Global Advisors LLC grew its holdings in China Biologic Products by 13.9% during the 2nd quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock worth $107,567,000 after acquiring an additional 137,484 shares during the last quarter. Vanguard Group Inc. grew its holdings in China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock worth $90,575,000 after acquiring an additional 29,178 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in China Biologic Products by 18.1% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 129,445 shares of the biopharmaceutical company’s stock worth $14,818,000 after acquiring an additional 19,846 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in China Biologic Products during the 2nd quarter worth about $8,749,000. Finally, Point72 Asset Management L.P. bought a new stake in China Biologic Products during the 2nd quarter worth about $6,477,000. 37.05% of the stock is currently owned by institutional investors and hedge funds.

CBPO traded up $0.30 on Tuesday, reaching $117.00. 71,900 shares of the company traded hands, compared to its average volume of 85,168. The company has a market cap of $4.59 billion, a price-to-earnings ratio of 29.10, a PEG ratio of 7.09 and a beta of 1.18. China Biologic Products has a 52-week low of $70.30 and a 52-week high of $119.44. The stock’s 50 day moving average price is $115.09 and its 200-day moving average price is $100.98.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.